ClinicalTrials.gg
Status unknownNCT03173833Updated Jun 2, 2017

Fulfilling Care Needs of Adolescents With Cancer

An interventional study of CAGO questionnaire outcome in Cancer, sponsored by National Taiwan University Hospital. Status unknown at 1 site in Taiwan. Open to participants aged 13 Years to 20 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-02.

Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Health services research

The sponsor has not verified this record recently (last verified Apr 2017), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
720
Allocation
Non-randomized
Ages
13 Years to 20 Years
Sex
All
01

Study summary

The aim of phase 1 of this study is to develop a care need scale (CNS) for adolescents with cancer. The aim of phase 2 is to examine the mediating role of care needs between physical and psychosocial dysfunction and QoL, and to explore the recovery trajectory and its predictors regarding the care needs, physical and psychosocial factors, and the QoL of adolescents with cancer at the first, second, and third 3-month periods after initiating on-treatment and off-treatment. The aim of phase 3 is to examine the effectiveness of the computerized assessment with graphic outcome (CAGO) for fulfilling the care needs of adolescents with cancer, its acceptability for adolescents with cancer, and its usability for clinicians in pediatric oncology units.

02

Conditions studied

  • Cancer

Browse trials for

Keywords

  • cancer patients, quality of life
03

In context

Neoplasms

9,610 studies on the registry are indexed under Neoplasms; 2,508 are open to participants now.

This study's planned enrollment of 720 is above the median of 50 across 7,429 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,608 studies on the registry; 573 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

The inclusion criteria for adolescents with cancer are

  1. 13-20 years of age
  2. previously or currently treated for cancer
  3. able to communicate in Chinese
  4. able to comprehend the study information
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
720 participants (estimated)

Study arms

  • No intervention
    Control group

    Participants will not receive the outcome of their questionnaire in the form of computerized assessment with graphic outcome (CAGO) after the first time they fill in the questionnaire. And they will be able to discuss their care needs with their health care practitioners.

  • Experimental
    Experimental group

    Participants will receive the outcome of their questionnaire in the form of computerized assessment with graphic outcome (CAGO) every time after the first time they fill in the questionnaire. And they will be able to discuss their care needs with their health care practitioners.

    Other: CAGO questionnaire outcome

Interventions

  • OtherCAGO questionnaire outcome

    Every time when cancer patients fulfill the following questionnaires, SDS, PTGI, CNS, PedsQL, the outcome of the questionnaires will be provided to the experimental group of the participants by using a computer assessment with graphic outcome.

    Also known as: computer assessment with graphic outcome (CAGO)

06

What researchers measure

Primary outcomes

  1. Symptom Distress Scale

    Time frame: 2 weeks

  2. Beck Youth Inventories second edition

    Time frame: 2 weeks

  3. Posttraumatic Growth Index

    Time frame: 2 weeks

  4. Resilience Scale

    Time frame: 2 weeks

  5. Care demand scale

    Time frame: 2 weeks

  6. Pediatric Quality of Life

    Time frame: 2 weeks

  7. Acceptability if E-scale

    Time frame: 2 weeks

  8. Usability scale

    Time frame: 2 weeks

07

Study locations

1 site
  • National Taiwan University Hospital
    Test1, Test2 test3, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2017; primary completion for Jul 2020, 35 months later.

Of 1,358 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 71. This study's planned 35 months is close to that.

Counting every sponsor, half of 1,404 studies reached it within 38 months; a quarter within 17 and three quarters within 71.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2017
First posted
Jun 2, 2017
StartEst.
Aug 1, 2017
Primary completionEst.
Jul 31, 2020
CompletionEst.
Jul 31, 2020
Last update
Jun 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03173833
Responsible party
Sponsor
First posted
Jun 2, 2017
Start date
Aug 1, 2017 (estimated)
Primary completion
Jul 31, 2020 (estimated)
Completion
Jul 31, 2020 (estimated)
Last update
Jun 2, 2017

Study contacts

Wei-Wen Wu
Contact
weiwen@ntu.edu.tw
2312-3456 ext. 88422
SHIANN-TARNG LOU
principal investigator · National Taiwan University Hospital Department of Pediatrics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion